Resistance to anti-EGFR monotherapy can arise due to different regulatory mechanisms that operate at the level of EGFR and its ligands, alternative parallel signaling pathways in the cells as well as the cross-talk between EGFR expressing cells and the tumor microenvironment 6. Here, EGFR is linked to neoplasm.